BioNTech & Pfizer Announce Phase 3 Vaccine Trial Results
Ticker: BNTX · Form: 6-K · Filed: Aug 16, 2024 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Aug 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, vaccine, collaboration
TL;DR
BioNTech and Pfizer dropped Phase 3 vaccine trial results, but details are scarce.
AI Summary
On August 16, 2024, BioNTech SE and Pfizer Inc. announced top-line results from their Phase 3 clinical trial for a combined vaccine. The filing does not provide specific details on the results or any associated dollar amounts.
Why It Matters
This announcement is significant as it pertains to the efficacy and potential market readiness of a new combined vaccine developed by two major pharmaceutical companies.
Risk Assessment
Risk Level: low — The filing is an update on clinical trial results and does not contain immediate financial or operational risks.
Key Players & Entities
- BioNTech SE (company) — Registrant and trial collaborator
- Pfizer Inc. (company) — Trial collaborator
- August 16, 2024 (date) — Date of announcement
FAQ
What were the top-line results of the Phase 3 clinical trial for the combined vaccine?
The filing states that top-line results were announced on August 16, 2024, but does not provide specific details of these results.
Which companies collaborated on this Phase 3 trial?
BioNTech SE and Pfizer Inc. collaborated on the Phase 3 clinical trial.
When was the announcement of the top-line results made?
The announcement was made on August 16, 2024.
What type of vaccine was evaluated in the Phase 3 trial?
The filing refers to a 'combined vaccine'.
Does this filing include financial details related to the vaccine trial?
No, this filing is an update on clinical trial results and does not include specific financial details or dollar amounts.
Filing Stats: 270 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2024-08-16 06:56:10
Filing Documents
- form6-kcombovaccineph23upd.htm (6-K) — 16KB
- ex99_120240816xbntxcombova.htm (EX-99.1) — 89KB
- image_0a.jpg (GRAPHIC) — 32KB
- image_1a.jpg (GRAPHIC) — 69KB
- 0001776985-24-000073.txt ( ) — 245KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On August 16 , 2024, BioNTech SE and Pfizer Inc. announced top-line results from their Phase 3 clinical trial to evaluate the companies' combined m RNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age . The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Jens Holstein By s Dr. Sierk Poetting Name Jens Holstein Name Dr. Sierk Poetting Title Chief Financial Officer Title Chief Operating Officer Date August 16, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age